Ursodeoxycholic acid administration in patients with cholestasis of pregnancy: Effects on primary bile acids in babies and mothers

142Citations
Citations of this article
61Readers
Mendeley users who have this article in their library.

Abstract

Little is known about the effects on the fetus of ursodeoxycholic acid (UDCA) treatment for intrahepatic cholestasis of pregnancy (ICP). Twenty ICP patients were given UDCA at 1.5 to 2 g/d, to our knowledge the highest dosage yet reported. Effects were evaluated on conjugated bile acids (BA) in amniotic fluid (15 of 20 patients) and umbilical cord serum obtained at delivery (20 of 22 newborns), as compared with 10 untreated patients (amniotic fluid, 9 of 10 patients; cord serum, 9 of 10 newborns). Liver function tests, serum BA and UDCA were evaluated on enrollment and then weekly until 1 week after delivery. Maternal serum conjugated cholic (CCA) and chenodeoxycholic (CCDCA) acids levels fell (18.5 ± 1.9 to 10.5 ± 1.9 μmol/L, and 5.8 ± 0.8 to 2.97 ± 0.7 μmol/L, respectively [P

Cite

CITATION STYLE

APA

Mazzella, G., Nicola, R., Francesco, A., Patrizia, S., Luciano, B., Anna, M., … Enrico, R. (2001). Ursodeoxycholic acid administration in patients with cholestasis of pregnancy: Effects on primary bile acids in babies and mothers. Hepatology, 33(3), 504–508. https://doi.org/10.1053/jhep.2001.22647

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free